Skip to main content
Clinical Trials/NCT00714974
NCT00714974CompletedNot Applicable

A Prospective, Randomized, Blinded Study of BIS Analysis in ICU Patients Requiring Neuromuscular Blocking Agents

University of Utah0 sites56 target enrollmentStarted: February 2000Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
56
Primary Endpoint
Amount of sedation required.

Study Overview

Brief Summary

This is a prospective, randomized, blinded study in which patients will be enrolled into either treated(BIS group) or untreated (non-BIS) group employing bispectral analysis to measure the level of sedation/analgesia in patients receiving neuromuscular blocking agents.

To collect pertinent data on critically ill patients while they are receiving NMBA's. In particular to correlate sedation/analgesic medication needs between a group whose medication use is determined by the values obtained by bispectral analysis to a group who will have medications delivered by the standard of care presently used in the intensive care unit in which they are being treated.

To document that patients who are monitored with bispectral analysis are able to achieve an appropriate level of consciousness in a shorter time and require less manipulation and amounts of sedative or analgesic medications than those who are not monitored.

Detailed Description

This is a prospective, randomized and blinded study being done in order to help evaluate the level of consciousness with bispectral analysis (BIS) in ICU patients who are pharmacologically paralyzed with NMBAs (neuromuscular blockade agents) and to assess such things as the amount of time required to achieve the appropriate level of sedation/analgesia. Data will be collected and evaluated via this FDA approved equipment. The intent of this project is to evaluate this technology in those who are requiring "anesthesia" like states (use of NMBAs) for prolonged periods in the critically ill patient population.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Consented ICU patient, receiving neuromuscular blocking agents.

Exclusion Criteria

  • Unable to be consented

Outcomes

Primary Outcomes

Amount of sedation required.

Time Frame: During period of neuromuscular blockade use in ICU

Secondary Outcomes

  • Time requiring neuromuscular blockade and mechanical ventilation.(Time in ICU)

Investigators

Sponsor Class
Other

Similar Trials